JUL 3 2026
Achieve Life Sciences — cytisinicline $ACHV
for nicotine dependence (smoking cessation)
Accepted SEP 3 2025.
About
Nicotine dependence is a chronic condition where the brain craves nicotine despite harmful consequences, leading to withdrawal symptoms and making quitting tobacco extremely difficult. Cytisinicline partially activates the same brain receptors as nicotine, reducing cravings without delivering the addictive substance. This approach may help smokers break their dependence by easing withdrawal while gradually weaning them off nicotine’s effects.
Pivotal trial
This placebo-controlled Phase 3 study is being conducted at sites within the United States to evaluate 3 mg cytisinicline 3 times daily (TID) for treatment duration of 42 days/6 weeks and evaluate 3 mg cytisinicline TID for treatment duration of 84 days/12 weeks.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on cytisinicline
- Achieve Life Sciences Presents Long-Term Safety Data for Cytisinicline in Smoking Cessation at ATS 2026 - Quiver Quantitative
- Year-long test of quit-smoking pill cytisinicline finds low nausea - Stock Titan
- Achieve Life Sciences presents long-term cytisinicline data - Investing.com
- Achieve Life Sciences, Inc.: cytisinicline data indicate well-tolerated safety over 52 weeks for adults quitting smoking - Traders Union
- Achieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA Resubmission - Seeking Alpha
Sponsor Watch — recent news on Achieve Life Sciences
- Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment
- Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Launches Up to $354 Million Private Placement; Names Andrew Goldberg CEO; Shares Rise
- Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors
- Achieve Life Sciences Announces Up to $354 Million Private Placement